| abstract |
The invention relates to the use of a selective dopamine DI receptor agonist for the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia. The invention further relates to the use of a selective dopamine DI receptor agonist for the manufacture of a pharmaceutical composition for the treatment of the abovementioned conditions. The invention further relates to pharmaceutical compositions which comprise as active agent a selective dopamine DI receptor agonist, for use in the treatment of each of the indicated conditions. |